Epithelial ovarian cancer – pipeline review, h2 2012Rose088
The document summarizes a market research report from Global Markets Direct titled "Epithelial Ovarian Cancer – Pipeline Review, H2 2012". The report provides an overview of the current therapeutic pipeline for epithelial ovarian cancer, including information on late stage projects, companies involved in development, and assessment of products by factors such as molecule type and administration route. It also lists key report sections such as executive summary, pipeline analysis, company profiles, and individual drug profiles.
The document announces the availability of a market research report on the pipeline of treatments for Keratitis from H1 2012. The report provides an overview of therapeutic developments for Keratitis, including both pharmaceutical and university projects at different stages of development. It also profiles companies involved in developing treatments for Keratitis and assesses the pipeline based on factors like route of administration and molecule type. Sample pages of the report can be requested by email.
The document summarizes a report on the veterinary diagnostics market. It describes how diagnostic tests play a key role in animal health and trade by detecting diseases. The global veterinary diagnostics market has grown steadily since the 2000s and is expected to continue growing. The market can be divided into companion animal and food animal health segments. The report provides market size data from 2006-2014 for regions including the US, Europe, and Asia. It also profiles major companies in the industry like Heska, Bio-Rad, IDEEX, and Prionics.
IUPHAR/BPS Guide to PHARMACOLOGY in 2017: new features and updatesGuide to PHARMACOLOGY
This document summarizes updates to the IUPHAR/BPS Guide to PHARMACOLOGY database. It provides expert curated data on human drug targets and ligands. Recent additions include new target families, ligands, and links to immunopharmacology data. New features include download options, search tools, and organization of ligand families. The database is maintained by an international team and network of scientists and provides a resource for pharmacology education and research.
These slides will be presented at the Pharmacology 2017 meeting in London during the following session:
Abstract Number: OB073
Abstract Title: Capturing new BIA 10-2474 molecular data in the IUPHAR/BPS Guide to PHARMACOLOGY
Date: Wednesday, December 13, 2017, 11:30 AM
Oral Session: Oral Communications: Mixed Tracks
United therapeutics corporation – product pipeline review – 2012Rose088
The document announces a market research report on United Therapeutics Corporation's product pipeline from 2012. The report provides data on United Therapeutics' research and development focus, including their current developmental pipeline, completed and discontinued projects. It describes United Therapeutics' pipeline across various therapy areas, and includes details on pipeline molecules in different development stages globally.
Biosimilars are biological products that are composed or produced in living systems such as yeast or bacteria. They are defined as the medicinal drugs which function exactly like certain existing and approved drugs, often referred to as “reference product”. The major facets which make up a biosimilar are that they are “highly similar” to their reference product and they should have no clinically significant differences from safety, efficiency, and functionality perspectives...
Macro genics, inc. – product pipeline review – 2012Rose088
This document summarizes a market research report about MacroGenics, Inc.'s product pipeline as of 2012. It provides an overview of MacroGenics' research areas, pipeline of products in development across various therapy areas and stages of the drug development process. It also includes brief profiles of some of MacroGenics' key pipeline products in development, such as DART for autoimmune disorders, DART mAbs, and monoclonal antibodies. The full report contains additional details on MacroGenics' pipeline like lists of tables and figures as well as related reports that can be purchased.
Epithelial ovarian cancer – pipeline review, h2 2012Rose088
The document summarizes a market research report from Global Markets Direct titled "Epithelial Ovarian Cancer – Pipeline Review, H2 2012". The report provides an overview of the current therapeutic pipeline for epithelial ovarian cancer, including information on late stage projects, companies involved in development, and assessment of products by factors such as molecule type and administration route. It also lists key report sections such as executive summary, pipeline analysis, company profiles, and individual drug profiles.
The document announces the availability of a market research report on the pipeline of treatments for Keratitis from H1 2012. The report provides an overview of therapeutic developments for Keratitis, including both pharmaceutical and university projects at different stages of development. It also profiles companies involved in developing treatments for Keratitis and assesses the pipeline based on factors like route of administration and molecule type. Sample pages of the report can be requested by email.
The document summarizes a report on the veterinary diagnostics market. It describes how diagnostic tests play a key role in animal health and trade by detecting diseases. The global veterinary diagnostics market has grown steadily since the 2000s and is expected to continue growing. The market can be divided into companion animal and food animal health segments. The report provides market size data from 2006-2014 for regions including the US, Europe, and Asia. It also profiles major companies in the industry like Heska, Bio-Rad, IDEEX, and Prionics.
IUPHAR/BPS Guide to PHARMACOLOGY in 2017: new features and updatesGuide to PHARMACOLOGY
This document summarizes updates to the IUPHAR/BPS Guide to PHARMACOLOGY database. It provides expert curated data on human drug targets and ligands. Recent additions include new target families, ligands, and links to immunopharmacology data. New features include download options, search tools, and organization of ligand families. The database is maintained by an international team and network of scientists and provides a resource for pharmacology education and research.
These slides will be presented at the Pharmacology 2017 meeting in London during the following session:
Abstract Number: OB073
Abstract Title: Capturing new BIA 10-2474 molecular data in the IUPHAR/BPS Guide to PHARMACOLOGY
Date: Wednesday, December 13, 2017, 11:30 AM
Oral Session: Oral Communications: Mixed Tracks
United therapeutics corporation – product pipeline review – 2012Rose088
The document announces a market research report on United Therapeutics Corporation's product pipeline from 2012. The report provides data on United Therapeutics' research and development focus, including their current developmental pipeline, completed and discontinued projects. It describes United Therapeutics' pipeline across various therapy areas, and includes details on pipeline molecules in different development stages globally.
Biosimilars are biological products that are composed or produced in living systems such as yeast or bacteria. They are defined as the medicinal drugs which function exactly like certain existing and approved drugs, often referred to as “reference product”. The major facets which make up a biosimilar are that they are “highly similar” to their reference product and they should have no clinically significant differences from safety, efficiency, and functionality perspectives...
Macro genics, inc. – product pipeline review – 2012Rose088
This document summarizes a market research report about MacroGenics, Inc.'s product pipeline as of 2012. It provides an overview of MacroGenics' research areas, pipeline of products in development across various therapy areas and stages of the drug development process. It also includes brief profiles of some of MacroGenics' key pipeline products in development, such as DART for autoimmune disorders, DART mAbs, and monoclonal antibodies. The full report contains additional details on MacroGenics' pipeline like lists of tables and figures as well as related reports that can be purchased.
This document provides an overview and summary of the global clinical laboratory instrumentation and reagent market. It examines segments from small lab equipment to highly automated large platforms and accessories like reagents. The emphasis is on companies and products actively developing and marketing clinical laboratory analyzers for hospitals, independent labs, doctors offices and clinics. The report focuses on the instrumentation industry market and companion reagent sector in the US, Europe, Asia and rest of world. It pays particular attention to areas showing the greatest growth and most innovation.
The document announces the availability of a market research report on the gastroenteritis therapeutic pipeline. The report provides an overview of developmental therapies for gastroenteritis, including late-stage and discontinued projects. It reviews key players and analyzes products under development by stage, administration route, and molecule type. Sample pages of the full report can be requested by email.
Sharing my learning in dealing with complexity and uncertainty and shed some light on:
(a) Understanding the ‘biosimilar paradox’
(b) Accelerating our “QbD” Journey – focusing on ‘from Generics to Biosimilars’
(c) In preparing this talk, collect my thoughts to help NIPTE consider ways for developing its program on Biosimilars to help the Nation improve assurance of quality with confidence and lower costs
(D) Invite the audience to get to know NIPTE and provide us ways to collaborate with industry
What are the need-to-know characteristics of regulatory, nonclinical and clinical specific to microbiome products? A transnational perspective
-Regulatory environment for microbiome products, Differences between USA and EU regulatory requirements;
-Microbiome products NC evaluation compared to drugs/ biologics NC evaluation: same objectives but different strategies;
- Regulatory NC considerations and approach;
-Take-home messages: integrated approach CMC / nonclinical / clinical
The document summarizes a market research report on Cytokinetics, Incorporated's product pipeline as of 2012. It provides an overview of Cytokinetics' research areas and developmental pipeline, including 5 drug candidates in clinical trials and 5 in pre-clinical development. The report details each drug candidate's description, mechanism of action, and development progress. It aims to give readers an understanding of Cytokinetics' pharmaceutical research and pipeline as of 2012.
Biosimilar current market and its future scopeGopal Agrawal
This document provides an overview of biosimilars including what they are, approval requirements, differences from generics, major companies involved, current and future market sizes with a focus on Europe which currently dominates the global biosimilar market. Key applications discussed are oncology, blood disorders, and autoimmune diseases. Recent advances and growth in Asia-Pacific region are also mentioned.
Ym bio sciences inc. – product pipeline review – 2012Rose088
This document summarizes a market research report on YM BioSciences Inc.'s product pipeline as of 2012. It provides an overview of YM BioSciences' business and focus on key therapeutic areas. The report also details YM's pipeline of candidates in various stages of clinical development, including Phase III, Phase II and Phase I trials, as well as combination treatment modalities. It profiles several of YM's lead pipeline candidates and outlines their mechanisms of action and development progress. Contact information is provided to request a sample of the full report or for additional related pharmaceutical reports.
Controlled release drug delivery market offers unexplored opportunitiesKuicK Research
“Controlled Release Drug Delivery Market & Pipeline Insight” Report Highlights:
Controlled Release Drug Delivery Market Overview
Controlled Release Drug Delivery Mechanism
Clinical Pipeline by Phase & Target Indications
Drug Profiles in Report: 451
Drug Profile in Active Clinical Phase (Research till Registration): 234
Majority of Controlled Release Drug in Phase-II Development: 58
Marketed Controlled Release Drugs: 140
Suspended & Discontinued Drug Profiles
“Challenges of biosimilar product development and experience gained”
Shows the development process for biosimilars, focusing specifically on the company’s experience
Please share this slideshow with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● Discussion on biologics, including an explanation of the high level of precision that is required to produce a consistent biological product each time.
● Discussion on the growing interest in biosimilars, followed by what we can learn from Europe’s experience.
● Health Canada’s position on biosimilars, discussion on key issues surrounding biosimilars relevant to the Canadian market.
● The importance of patient safety and patient choice.
View the video: https://youtu.be/h3Ap6HoiSC8
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
The Biologics Market was worth USD 267.58 billion in 2014 and is expected to reach approximately USD 373.66 billion by 2023, while registering itself at a compound annual growth rate (CAGR) of 3.78% during the forecast period. Biologics are medicates as hereditarily built proteins, got from human qualities. According to the US FDA, biologics can be made out of sugars, proteins, or nucleic acids or complex blends of these substances, or might live elements, for example, cells and tissues. The biologic medications are taken from an assortment of regular sources, for example, people, creatures, or microorganisms and comprise of items, for example, antibodies, blood and blood parts, allergenic, substantial cells, quality treatment, tissues, and recombinant remedial proteins. Propelled biotechnology strategies and complex procedures are utilized to produce biologics. They are at the cutting edge of biomedical research.
Controlled drug release market to grow exponentiallyKuicK Research
“Controlled Release Drug Delivery Market & Pipeline Insight” Report Highlights:
Controlled Release Drug Delivery Market Overview
Controlled Release Drug Delivery Mechanism
Clinical Pipeline by Phase & Target Indications
Drug Profiles in Report: 451
Drug Profile in Active Clinical Phase (Research till Registration): 234
Majority of Controlled Release Drug in Phase-II Development: 58
Marketed Controlled Release Drugs: 140
Suspended & Discontinued Drug Profiles
Searching for chemical information using PubChemSunghwan Kim
Presented at the 257th American Chemical Society (ACS) National Meeting in Orlando, FL (April 1, 2019). [CHED 303]
==== Abstract ====
PubChem (https://pubchem.ncbi.nlm.nih.gov) is a public chemical database, which provides information on a broad range of chemical entities, including small molecules, lipids, carbohydrates, and (chemically-modified) amino acid and nucleic acid sequences (including siRNA and miRNA). With three million unique users per month at peak, PubChem is ranked as one of the most visited chemistry websites in the world. A substantial number of PubChem users are between ages 18 and 24, who are likely to be undergraduate or graduate students at academic institutions. Therefore, PubChem has a great potential as an online resource for chemical education. In this talk, we will present “PubChem Search”, a new web interface that allows users to quickly find desired chemical information. This interface supports chemical name search as well as various types of chemical structure search, including identity/similarity search, superstructure/substructure search, and molecular search. Using PubChem Search, it is also possible to search for journal articles or patent documents that mention a given chemical. The hits returned from a search can be downloaded to local machines or further refined or analyzed in conjunction with other PubChem tools and services. In this presentation, we will demonstrate how the PubChem Search interface can be used to search beyond google for chemical information of interest.
ChemSpider is being built with the intention of being a chemical structure centric community for chemists. With over 16 million chemical structures as of August 2007, and with data deposition and curation mechanisms in place for text, structure and spectra ChemSpider intends to be a meeting place and collaborative environment for chemists to work together.
11 years old presentation submitted as Project work: Golden Mantra to Perform Worldwide Patent Searches
Patent provides the right to exclude others from making, using, selling, offering for sale, or importing the patented invention for the term of the patent, usually 20 years from the filing date. A patent is, in effect, a limited property right that the government offers to inventors in exchange for their agreement to share the details of their inventions with the public. Like any other property right, it may be sold, licensed, mortgaged, assigned or transferred, given away, or simply abandoned.
In order to obtain a patent, an applicant must provide a written description of his or her invention in sufficient detail for a person skilled in the art (i.e., the relevant area of technology) to make and use the invention.
The Clinical Pharmacogenetics Implementation Consortium (CPIC) was formed in 2009 between PharmGKB and the Pharmacogenomics Research Network to address barriers to implementing pharmacogenetic tests in clinical practice. CPIC publishes peer-reviewed guidelines in a journal and on PharmGKB for using genetic information in drug therapy. Their guidelines provide gene-drug pairs and contact information for authors on published and underway guidelines to help with pharmacogenomic treatment.
EUGM15 - George Papadatos, Mark Davies, Nathan Dedman (EMBL-EBI): SureChEMBL:...ChemAxon
SureChEMBL is a new resource provided by the European Bioinformatics Institute (EMBL-EBI) that annotates, extracts and indexes chemistry from full text patent documents by means of continuous, automated text and image mining. SureChEMBL is perhaps the only open, freely available, live patent chemistry resource available, in a field that has been traditionally commercial.
Since its launch last September, the SureChEMBL interface provides sophisticated keyword and chemistry-based querying and exporting functionality against a corpus of more than 16 million compounds extracted from 13 million patent documents. Both the interface and the underlying data pipeline leverage extensively ChemAxon technologies for name to structure conversion, as well as compound standardisation, registration and searching.
In addition to providing an overview of the system, recent developments and improvements will be described. These include the introduction of various data interexchange and exporting options, such as flat files and a data feed client. Furthermore, our future plans for the SureChEMBL system will be outlined. To date, such plans include complementing the chemical annotations with biological ones, covering genes, proteins, diseases and indications. Furthermore, we are planning to further enrich the chemical annotations with a relevance score, indicating their importance in the patent document.
PubChem is a key chemical information resource at the National Center for Biotechnology Information that contains 247.3 million substance descriptions, 96.5 million unique chemical structures, and 237 million bioactivity test results. It organizes data into the Substance, Compound, and BioAssay databases. PubChem provides search and analysis tools for its extensive and growing collection of chemical and biological data.
The document summarizes a market research report from Global Markets Direct titled "Refractory Multiple Myeloma - Pipeline Review, H2 2012". The report provides an overview of the therapeutic pipeline for refractory multiple myeloma, including late-stage and discontinued projects. It reviews key players and their development of treatments, which are organized by stage of development. Tables of contents and figures are also included.
The document announces the availability of a market research report on the pipeline of treatments for bacteremia from Aarkstore.com, providing an overview of therapeutic developments for bacteremia in clinical trials and by development stage, company, and drug properties. It also lists other related pipeline reports and contact information for the publisher.
This document provides an overview and summary of the global clinical laboratory instrumentation and reagent market. It examines segments from small lab equipment to highly automated large platforms and accessories like reagents. The emphasis is on companies and products actively developing and marketing clinical laboratory analyzers for hospitals, independent labs, doctors offices and clinics. The report focuses on the instrumentation industry market and companion reagent sector in the US, Europe, Asia and rest of world. It pays particular attention to areas showing the greatest growth and most innovation.
The document announces the availability of a market research report on the gastroenteritis therapeutic pipeline. The report provides an overview of developmental therapies for gastroenteritis, including late-stage and discontinued projects. It reviews key players and analyzes products under development by stage, administration route, and molecule type. Sample pages of the full report can be requested by email.
Sharing my learning in dealing with complexity and uncertainty and shed some light on:
(a) Understanding the ‘biosimilar paradox’
(b) Accelerating our “QbD” Journey – focusing on ‘from Generics to Biosimilars’
(c) In preparing this talk, collect my thoughts to help NIPTE consider ways for developing its program on Biosimilars to help the Nation improve assurance of quality with confidence and lower costs
(D) Invite the audience to get to know NIPTE and provide us ways to collaborate with industry
What are the need-to-know characteristics of regulatory, nonclinical and clinical specific to microbiome products? A transnational perspective
-Regulatory environment for microbiome products, Differences between USA and EU regulatory requirements;
-Microbiome products NC evaluation compared to drugs/ biologics NC evaluation: same objectives but different strategies;
- Regulatory NC considerations and approach;
-Take-home messages: integrated approach CMC / nonclinical / clinical
The document summarizes a market research report on Cytokinetics, Incorporated's product pipeline as of 2012. It provides an overview of Cytokinetics' research areas and developmental pipeline, including 5 drug candidates in clinical trials and 5 in pre-clinical development. The report details each drug candidate's description, mechanism of action, and development progress. It aims to give readers an understanding of Cytokinetics' pharmaceutical research and pipeline as of 2012.
Biosimilar current market and its future scopeGopal Agrawal
This document provides an overview of biosimilars including what they are, approval requirements, differences from generics, major companies involved, current and future market sizes with a focus on Europe which currently dominates the global biosimilar market. Key applications discussed are oncology, blood disorders, and autoimmune diseases. Recent advances and growth in Asia-Pacific region are also mentioned.
Ym bio sciences inc. – product pipeline review – 2012Rose088
This document summarizes a market research report on YM BioSciences Inc.'s product pipeline as of 2012. It provides an overview of YM BioSciences' business and focus on key therapeutic areas. The report also details YM's pipeline of candidates in various stages of clinical development, including Phase III, Phase II and Phase I trials, as well as combination treatment modalities. It profiles several of YM's lead pipeline candidates and outlines their mechanisms of action and development progress. Contact information is provided to request a sample of the full report or for additional related pharmaceutical reports.
Controlled release drug delivery market offers unexplored opportunitiesKuicK Research
“Controlled Release Drug Delivery Market & Pipeline Insight” Report Highlights:
Controlled Release Drug Delivery Market Overview
Controlled Release Drug Delivery Mechanism
Clinical Pipeline by Phase & Target Indications
Drug Profiles in Report: 451
Drug Profile in Active Clinical Phase (Research till Registration): 234
Majority of Controlled Release Drug in Phase-II Development: 58
Marketed Controlled Release Drugs: 140
Suspended & Discontinued Drug Profiles
“Challenges of biosimilar product development and experience gained”
Shows the development process for biosimilars, focusing specifically on the company’s experience
Please share this slideshow with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● Discussion on biologics, including an explanation of the high level of precision that is required to produce a consistent biological product each time.
● Discussion on the growing interest in biosimilars, followed by what we can learn from Europe’s experience.
● Health Canada’s position on biosimilars, discussion on key issues surrounding biosimilars relevant to the Canadian market.
● The importance of patient safety and patient choice.
View the video: https://youtu.be/h3Ap6HoiSC8
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
The Biologics Market was worth USD 267.58 billion in 2014 and is expected to reach approximately USD 373.66 billion by 2023, while registering itself at a compound annual growth rate (CAGR) of 3.78% during the forecast period. Biologics are medicates as hereditarily built proteins, got from human qualities. According to the US FDA, biologics can be made out of sugars, proteins, or nucleic acids or complex blends of these substances, or might live elements, for example, cells and tissues. The biologic medications are taken from an assortment of regular sources, for example, people, creatures, or microorganisms and comprise of items, for example, antibodies, blood and blood parts, allergenic, substantial cells, quality treatment, tissues, and recombinant remedial proteins. Propelled biotechnology strategies and complex procedures are utilized to produce biologics. They are at the cutting edge of biomedical research.
Controlled drug release market to grow exponentiallyKuicK Research
“Controlled Release Drug Delivery Market & Pipeline Insight” Report Highlights:
Controlled Release Drug Delivery Market Overview
Controlled Release Drug Delivery Mechanism
Clinical Pipeline by Phase & Target Indications
Drug Profiles in Report: 451
Drug Profile in Active Clinical Phase (Research till Registration): 234
Majority of Controlled Release Drug in Phase-II Development: 58
Marketed Controlled Release Drugs: 140
Suspended & Discontinued Drug Profiles
Searching for chemical information using PubChemSunghwan Kim
Presented at the 257th American Chemical Society (ACS) National Meeting in Orlando, FL (April 1, 2019). [CHED 303]
==== Abstract ====
PubChem (https://pubchem.ncbi.nlm.nih.gov) is a public chemical database, which provides information on a broad range of chemical entities, including small molecules, lipids, carbohydrates, and (chemically-modified) amino acid and nucleic acid sequences (including siRNA and miRNA). With three million unique users per month at peak, PubChem is ranked as one of the most visited chemistry websites in the world. A substantial number of PubChem users are between ages 18 and 24, who are likely to be undergraduate or graduate students at academic institutions. Therefore, PubChem has a great potential as an online resource for chemical education. In this talk, we will present “PubChem Search”, a new web interface that allows users to quickly find desired chemical information. This interface supports chemical name search as well as various types of chemical structure search, including identity/similarity search, superstructure/substructure search, and molecular search. Using PubChem Search, it is also possible to search for journal articles or patent documents that mention a given chemical. The hits returned from a search can be downloaded to local machines or further refined or analyzed in conjunction with other PubChem tools and services. In this presentation, we will demonstrate how the PubChem Search interface can be used to search beyond google for chemical information of interest.
ChemSpider is being built with the intention of being a chemical structure centric community for chemists. With over 16 million chemical structures as of August 2007, and with data deposition and curation mechanisms in place for text, structure and spectra ChemSpider intends to be a meeting place and collaborative environment for chemists to work together.
11 years old presentation submitted as Project work: Golden Mantra to Perform Worldwide Patent Searches
Patent provides the right to exclude others from making, using, selling, offering for sale, or importing the patented invention for the term of the patent, usually 20 years from the filing date. A patent is, in effect, a limited property right that the government offers to inventors in exchange for their agreement to share the details of their inventions with the public. Like any other property right, it may be sold, licensed, mortgaged, assigned or transferred, given away, or simply abandoned.
In order to obtain a patent, an applicant must provide a written description of his or her invention in sufficient detail for a person skilled in the art (i.e., the relevant area of technology) to make and use the invention.
The Clinical Pharmacogenetics Implementation Consortium (CPIC) was formed in 2009 between PharmGKB and the Pharmacogenomics Research Network to address barriers to implementing pharmacogenetic tests in clinical practice. CPIC publishes peer-reviewed guidelines in a journal and on PharmGKB for using genetic information in drug therapy. Their guidelines provide gene-drug pairs and contact information for authors on published and underway guidelines to help with pharmacogenomic treatment.
EUGM15 - George Papadatos, Mark Davies, Nathan Dedman (EMBL-EBI): SureChEMBL:...ChemAxon
SureChEMBL is a new resource provided by the European Bioinformatics Institute (EMBL-EBI) that annotates, extracts and indexes chemistry from full text patent documents by means of continuous, automated text and image mining. SureChEMBL is perhaps the only open, freely available, live patent chemistry resource available, in a field that has been traditionally commercial.
Since its launch last September, the SureChEMBL interface provides sophisticated keyword and chemistry-based querying and exporting functionality against a corpus of more than 16 million compounds extracted from 13 million patent documents. Both the interface and the underlying data pipeline leverage extensively ChemAxon technologies for name to structure conversion, as well as compound standardisation, registration and searching.
In addition to providing an overview of the system, recent developments and improvements will be described. These include the introduction of various data interexchange and exporting options, such as flat files and a data feed client. Furthermore, our future plans for the SureChEMBL system will be outlined. To date, such plans include complementing the chemical annotations with biological ones, covering genes, proteins, diseases and indications. Furthermore, we are planning to further enrich the chemical annotations with a relevance score, indicating their importance in the patent document.
PubChem is a key chemical information resource at the National Center for Biotechnology Information that contains 247.3 million substance descriptions, 96.5 million unique chemical structures, and 237 million bioactivity test results. It organizes data into the Substance, Compound, and BioAssay databases. PubChem provides search and analysis tools for its extensive and growing collection of chemical and biological data.
The document summarizes a market research report from Global Markets Direct titled "Refractory Multiple Myeloma - Pipeline Review, H2 2012". The report provides an overview of the therapeutic pipeline for refractory multiple myeloma, including late-stage and discontinued projects. It reviews key players and their development of treatments, which are organized by stage of development. Tables of contents and figures are also included.
The document announces the availability of a market research report on the pipeline of treatments for bacteremia from Aarkstore.com, providing an overview of therapeutic developments for bacteremia in clinical trials and by development stage, company, and drug properties. It also lists other related pipeline reports and contact information for the publisher.
Sym bio pharmaceuticals limited – product pipeline review – 2012Rose088
The document announces a market research report from Global Markets Direct on SymBio Pharmaceuticals Limited's product pipeline. It provides an overview of SymBio's research areas and current developmental pipeline, including drug candidates in various stages of clinical trials for conditions like cancer. The report is based on proprietary data from Global Markets Direct as well as information from SymBio's corporate resources, and provides snapshots of individual drug candidates in development.
This document summarizes a market research report on the pipeline of therapies for amyloidosis. The report provides an overview of therapeutic candidates in development for amyloidosis, including their current stage of development. It analyzes pipeline products by company and university, and profiles major companies involved in developing treatments for this condition, such as GlaxoSmithKline, Isis Pharmaceuticals, and Alnylam Pharmaceuticals. Sample pages of the report can be requested by email for review.
The document summarizes a market research report on the pipeline of treatments for hypercalcemia. The report provides an overview of therapeutic developments for hypercalcemia, including late-stage and discontinued projects. It reviews key players involved in developing treatments and provides a snapshot of the global landscape, including products in development by stage and therapeutic approach. Sample pages of the full report can be requested from the publisher.
The document provides an overview of the global liquid biopsy market forecast from 2020 to 2025. It discusses key aspects of the market such as application, end user, clinical application, product/service, circulating biomarker, technology, and region. It also profiles major companies in the market and their recent developments. The global liquid biopsy market is expected to grow significantly due to the rising adoption of non-invasive cancer screening and monitoring techniques. However, lack of standardization and low reimbursement rates may hinder the market growth.
The global breast cancer liquid biopsy market is to increase from US$ 268.3 million in 2020 to US$ 677.3 million by 2025 with a compound annual growth rate (CAGR) of 20.3% for the period 2020-2025. The development of new cancer drugs by making viable treatment choices due to increased research and development (R&D) activities catalyse the market growth for breast cancer liquid biopsy. It is used to recognize or catch the intact genomics history of breast cancers, or to diagnose cancerous biomarkers at an early stage to better provide successful prevention and healthcare services. According to the World Health Organisation (WHO), breast cancer is one of the most prevalent forms of cancer in women, with about 2.1 million women suffering from breast cancer each year. Also, in 2018, nearly 627,000 people died of breast cancer. As a result, the increased case of breast cancer is expected to accelerate the need for breast cancer liquid biopsy. The research report on the global breast cancer liquid biopsy industry provides extensive competition analysis and competitive conditions. The report includes information on significant products, players, challenges and developments, and other information specific to the breast cancer liquid biopsy industry. The data in this report is targeted for business and industry practitioners and specifically intended to assist in the explanation, direction, and to understand of the potential of the breast cancer liquid biopsy markets. The study focuses on providing readers with an understanding of developments in the industry, market segments, market forecasts, leading players, and market drivers and inhibitors.
This document announces the availability of a market research report on Shire Plc's product pipeline as of 2012. The report provides an overview of Shire's research areas and pipeline of drugs in development, including those in late stage registration and clinical trials. It includes profiles for several of Shire's pipeline drugs in development, describing their purpose, mechanisms of action, and research progress. Contact information is provided to request a sample or purchase the full report.
Global cancer antibody drug conjugates market and pipeline insight 2022KuicK Research
“Global Cancer Antibody Drug Conjugate Market and Clinical Pipeline Insight 2022” report highlights:
Impetus of Antibody Drug Conjugates
Mechanism of Cancer Antibody Drug Conjugates
Global Cancer Antibody Drug Conjugate Clinical Pipeline Overview
Marketed Cancer Antibody Drug Conjugate Clinical Insight
Global Cancer Antibody Drug Conjugate Pipeline by Company, Indication , Mode of Action, Formulation and Phase
The document announces the availability of a market research report on the pipeline of treatments for mixed dyslipidemia from Global Markets Direct, which provides an overview of experimental therapies in development including their development stages and companies involved. It gives details on the scope and contents of the report such as sections on products by development stage, company, administration route, and individual drug profiles. Contact information is provided to request a sample of the full report.
This document summarizes a market research report on the product pipeline of Zydus Cadila Healthcare Limited. The report provides details on Zydus Cadila's research areas and developmental pipeline, including current projects in various stages of development across different therapy areas. It also lists several of Zydus Cadila's pipeline candidates, including their descriptions and development progress. Contact information is provided for requesting a sample of the full market research report.
Global antibody drug conjugate market & pipeline insight2020KuicK Research
" Global Antibody Drug Conjugate Market & Pipeline Insight 2020" Report Highlight:
Global Antibody Drug Conjugates Market Overview
Mechanism of Antibody Drug Conjugates
Global Antibody Drug Conjugates Clinical Pipeline by Company, Indication & Phase
Global Antibody Drug Conjugates Clinical Pipeline: 148 ADC
Marketed Antibody Drug Conjugates Clinical Insight: 8 ADC
Antibody Drug Conjugates Patent Analysis
Global Antibody Drug Conjugates Market Future Prospects
Download Global antibody drug conjugate market & pipeline insight2020KuicK Research
\" Global Antibody Drug Conjugate Market & Pipeline Insight 2020\" Report Highlight:
Global Antibody Drug Conjugates Market Overview
Mechanism of Antibody Drug Conjugates
Global Antibody Drug Conjugates Clinical Pipeline by Company, Indication & Phase
Global Antibody Drug Conjugates Clinical Pipeline: 148 ADC
Marketed Antibody Drug Conjugates Clinical Insight: 8 ADC
Antibody Drug Conjugates Patent Analysis
Global Antibody Drug Conjugates Market Future Prospects
Immuno gen, inc. – product pipeline review – 2012Rose088
The document summarizes a market research report on ImmunoGen, Inc.'s product pipeline as of 2012. It provides an overview of ImmunoGen's research areas and developmental pipeline, including current projects in various stages of development for cancer treatments. The report is compiled using data from ImmunoGen's corporate resources as well as third party sources, and includes profiles for several of ImmunoGen's lead pipeline candidates with details on their descriptions, mechanisms of action, and research progress. Links are also provided to other related product pipeline reports available.
This report provides an overview of the global pipeline for treatments of penile cancer. It details products in development from discovery through registration stages, including late and early clinical stage products. The report analyzes the pipeline based on factors like therapeutic class, administration route, and molecule type. It also profiles several late-stage pipeline products and provides company and drug descriptions. The report aims to help companies plan business strategies around the penile cancer therapeutic landscape.
The document announces a market research report from Aarkstore.com titled "Vaxon Biotech – Product Pipeline Review – 2012". The report provides data on Vaxon Biotech's research and development focus, including their current developmental pipeline with latest updates. It also includes information on discontinued and dormant projects. The report scope covers Vaxon Biotech's overview, review of their current human therapeutic pipeline, and coverage of pipeline molecules in various stages of drug development across different therapy areas.
This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects.
http://www.researchmoz.us/brain-cancer-pipeline-review-h1-2015-report.html
Viventia biotechnologies inc. – product pipeline review – 2012Rose088
The document announces a market research report from Global Markets Direct on Viventia Biotechnologies Inc.'s product pipeline. It provides an overview of Viventia's R&D focus and current developmental pipeline, including drug candidates in various stages of development across different therapy areas. The report is based on information from Viventia's corporate resources as well as Global Markets Direct's proprietary databases and analysis. It includes detailed profiles of Viventia's pipeline drugs with descriptions, mechanisms of action, and development progress.
Ziopharm oncology, inc. – product pipeline review – 2012Rose088
The document summarizes a market research report on ZIOPHARM Oncology, Inc.'s product pipeline as of 2012. It provides an overview of ZIOPHARM's research areas and developmental pipeline, including projects in various stages of development across different therapy areas. The report also includes snapshots of key pipeline candidates such as Ad-IL-12 and DC-IL-12, along with their descriptions, mechanisms of action, and research progress. Tables of contents and figures from the full report are listed as well.
This document summarizes a market research report from Global Markets Direct about Incyte Corporation's product pipeline as of 2012. It provides an overview of Incyte's research areas and pipeline of drug candidates, including those in late-stage development and clinical trials. Key information is given about Incyte's business and locations. The full report contains additional details on pipeline candidates like mechanisms of action, development progress updates, and discontinued projects. It also includes tables, figures and references to related reports available from the publisher.
Similar to Muscle invasive bladder cancer (mibc) – pipeline review, h2 2012 (20)
India wellness industry outlook 2016 robust growth in alternativeRose088
The document provides information on a report titled "India Wellness Industry Outlook 2016 – Robust Growth in Alternative Therapy and Nutraceuticals Market". The 123-page report can be purchased for $900 in PDF format, $1200 in hard copy format, or $1650 for an enterprise license. It provides an analysis of the Indian wellness industry market size and segmentation, including categories like fitness, spa services, alternative therapies, cosmetics, and nutraceuticals. The wellness industry in India grew by 16.9% in 2011, particularly among urban residents aged 25-49. The report also covers industry trends, projections, and the market for specific segments like fitness and slimming.
India waste management and recycling market outlook to 2016Rose088
The document summarizes a report on the India Waste Management and Recycling Market Outlook from 2006-2016. The 110-page report provides an analysis of the waste industry in India, focusing on municipal solid waste, industrial hazardous waste, e-waste, and bio medical waste. It details the market size and segmentation of the waste management sector in India. Key topics covered include market sizes and projections, regulations, trends, and the competitive landscape of major players. The report analyzes factors influencing industry growth and provides future projections for waste industry segments in India.
The document discusses a report on the pipeline of treatments for Hereditary Angioedema (HAE), including 82 pages on products in development from discovery to registration, with details on companies and universities involved, 20% discounts on reports over $1000, and contact information for sample reports or questions.
The document summarizes a report on the global pipeline of treatments for congestive heart failure (CHF) in the second half of 2012. The 290-page report provides an overview of CHF and treatments currently in development, including those in late stages of testing. It profiles key companies and universities researching new CHF therapies and analyzes products at different stages of development. The report aims to help identify emerging treatments and players to inform strategic decision-making around mergers, acquisitions and competitive strategies. It is available for purchase at prices ranging from $2000 to $6000 depending on the license. Contact information is provided to request a sample or related reports on other drug pipelines.
This document summarizes a 106-page report on the pipeline of therapeutics under development for acute renal failure (ARF)/acute kidney injury. The report provides an overview of the therapeutic pipeline as of the second half of 2012, including details on late-stage, mid-clinical stage, early clinical stage, and pre-clinical products. It reviews key players and universities involved in developing treatments for ARF/acute kidney injury and allows identification of emerging companies. The report can be purchased for various license fees or a sample may be requested.
Downstream processing in biopharmaceuticals adoptionRose088
This document summarizes a report from GBI Research about downstream processing in biopharmaceuticals. It discusses the adoption of disposable technologies at larger economies of scale to optimize production efficiency and cost-effectiveness. The report provides an overview of the biopharmaceutical and contract manufacturing industries as well as the downstream processing and reagent markets. It also includes market data, forecasts, profiles of key players, and an analysis of drivers and restraints. The report aims to help readers develop market strategies and understand factors shaping the industries.
The document summarizes a market research report on the Chinese markets for industrial lubricants. It examines China's economic trends, industry development, supply and demand for industrial lubricants in China. The report provides historical data from 2001 to 2011 and forecasts through 2016 and 2021. It profiles major lubricant producers in China and analyzes the industrial lubricants industry capacity, market share, technology development and major end-users. The full report is available for 50% off at $2000 and contains sections on business environment, industry assessments, and production and demand for various industrial lubricants.
This document summarizes a book about national security in Mumbai. It includes 18 chapters covering various sectors like transport, power, telecom, and others. It discusses security requirements and challenges for each sector. The book aims to assess the implications of security technologies and develop an effective system to address emerging threats. It also includes security requirements for Indian states, union territories, and some other countries.
Topo target a s – product pipeline review – 2012Rose088
The document summarizes a market research report from Global Markets Direct about the product pipeline of TopoTarget A/S, a pharmaceutical company. The report provides details on TopoTarget's current developmental pipeline, including projects in clinical trials and pre-clinical research across various therapy areas. It also profiles several of TopoTarget's key pipeline drugs and combination treatment modalities in development, including their descriptions, mechanisms of action, and research progress. Contact information is provided to request a sample of the full report or for questions.
The document announces the availability of a market research report on the Astrocytoma therapeutic pipeline from Global Markets Direct. The report provides an overview and details on drug candidates in development for Astrocytoma, including those from companies and universities. It covers products from discovery to registration stages and key players involved. Sample pages of the report can be requested by email.
Ipsen inc. – product pipeline review – 2012Rose088
This document summarizes a market research report on Ipsen Inc.'s product pipeline in 2012. The report provides an overview of Ipsen's research areas and pipeline of drugs in development, including those in Phase III clinical trials. It also lists Ipsen's locations and subsidiaries. The document encourages requesting a sample of the full market research report or searching for similar reports on pharmaceutical pipelines and healthcare topics through the Aarkstore website.
This document summarizes a market research report on MethylGene Inc's product pipeline as of 2012. The report provides details on MethylGene's research areas and pipeline of drug candidates at various stages of clinical trials. It describes several of MethylGene's lead drug candidates, including their mechanisms of action and development progress. Tables of contents and figures are included listing the report's contents. Contact information is provided to request a sample or purchase the full report.
This document summarizes a market research report on MerLion Pharmaceuticals Pte Ltd's product pipeline as of 2012. The report provides an overview of MerLion's research areas and developmental pipeline, including both current and discontinued/dormant projects. It describes the various stages of drug development for molecules across MerLion's portfolio in therapeutic areas such as anti-virulence, antibiotics, and anti-fungals. Tables and figures in the report provide additional details on MerLion's clinical and early-stage pipeline products. Contact information is provided for inquiries about purchasing the full report.
This document summarizes a market research report on Glenmark Pharmaceuticals Ltd's product pipeline as of 2012. The report provides details on Glenmark's research areas and pipeline of drug candidates at various stages of development, including 4 drugs in late-stage Phase III trials and several others in early-stage pre-clinical testing. Tables of contents and figures are included listing the pipeline drugs and studies. Contact information is provided to request a sample or related reports on pharmaceutical company pipelines and products.
This document summarizes a market research report from Global Markets Direct about Geron Corporation's product pipeline as of 2012. The report provides an overview of Geron's research areas and pipeline of drug candidates, including those in clinical trials for cancer and other conditions. It describes five of Geron's lead candidates in development - GRN1005, GRN163L, a combination of GRN163L with paclitaxel and bevacizumab, a combination of GRN163L with paclitaxel and carboplatin, and GRN510. Details provided on each candidate include its description, mechanism of action, and development progress.
7 tm pharma as – product pipeline review – 2012Rose088
The document summarizes a market research report on the product pipeline of 7TM Pharma A/S, a pharmaceutical company. It provides details on 7TM Pharma's current pipeline, including developmental stages of pipeline products across various therapy areas. Key pipeline molecules discussed include a drug for metabolic disorders, PAD program, TM30339, TM30510, and TM38837. The report also analyzes 7TM Pharma's research and development focus and pipeline.
The document announces the availability of a new market research report from GBI Research titled "Emerging Power Markets in South-East Asia, Middle East and Africa to 2020 - Government’s Restructuring Reforms Encouraging Private Participation will Enhance Price Competition and Efficiency". The report provides an analysis of the power markets, regulatory frameworks, and forecasts for installed capacity and generation in 7 countries in those regions through 2020. It also includes details on consumption, tables of contents, and links to other related reports.
The document summarizes a market research report from GBI Research about how cloud computing can optimize data management in pharmaceutical research and development, particularly for next-generation DNA sequencing and clinical trials data; it provides an overview of cloud computing technologies and models as well as applications in the pharmaceutical industry and competitive landscape of major cloud computing providers.
Mundipharma international limited – product pipeline review – 2012Rose088
The document announces the availability of a market research report on Mundipharma International Limited's product pipeline as of 2012. The report provides an overview of Mundipharma's research and development focus areas and current developmental pipeline, including projects in various stages of development across therapeutic areas. It includes a snapshot of Mundipharma, descriptions of pipeline products like Bendamustine Hydrochloride and Flutiform, and contact information for requesting a sample of the full report.
This document summarizes a market research report on Actelion Ltd's product pipeline as of 2012. The report provides an overview of Actelion's research areas and pipeline of drugs in development, including those in Phase I, II, and III clinical trials. It also profiles several of Actelion's lead pipeline candidates, describing their purpose, mechanisms of action, and development progress. The full report contains additional details on Actelion's pipeline such as tables, figures, and individual drug profiles.
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
Adhd Medication Shortage Uk - trinexpharmacy.comreignlana06
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central19various
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Osteoporosis - Definition , Evaluation and Management .pdfJim Jacob Roy
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
- Video recording of this lecture in English language: https://youtu.be/Pt1nA32sdHQ
- Video recording of this lecture in Arabic language: https://youtu.be/uFdc9F0rlP0
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Our backs are like superheroes, holding us up and helping us move around. But sometimes, even superheroes can get hurt. That’s where slip discs come in.
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Muscle invasive bladder cancer (mibc) – pipeline review, h2 2012
1. Aarkstore.com announces, The Latest market research report is available in
its vast collection:
Muscle Invasive Bladder Cancer (MIBC) – Pipeline Review, H2
2012
http://www.aarkstore.com/reports/Muscle-Invasive-Bladder-Cancer-MIBC-
Pipeline-Review-H2-2012-220602.html
RSS link of Global Markets Direct
http://www.aarkstore.com/feeds/Global-Markets-Direct.xml
Summary
Global Markets Direct’s, Muscle Invasive Bladder Cancer (MIBC) - Pipeline Review,
H2 2012, provides an overview of the Muscle Invasive Bladder Cancer (MIBC)
therapeutic pipeline. This report provides information on the therapeutic
development for Muscle Invasive Bladder Cancer (MIBC), complete with latest
updates, and special features on late-stage and discontinued projects. It also reviews
key players involved in the therapeutic development for Muscle Invasive Bladder
Cancer (MIBC). Muscle Invasive Bladder Cancer (MIBC) - Pipeline Review, H2 2012
is built using data and information sourced from Global Markets Direct’s proprietary
databases, Company/University websites, SEC filings, investor presentations and
featured press releases from company/university sites and industry-specific third
party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the
availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Muscle Invasive Bladder Cancer
(MIBC).
- A review of the Muscle Invasive Bladder Cancer (MIBC) products under
2. development by companies and universities/research institutes based on
information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from
discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined
therapeutics.
- Coverage of the
Table of contents:
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Muscle Invasive Bladder Cancer (MIBC) Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Muscle Invasive Bladder Cancer (MIBC) 7
Muscle Invasive Bladder Cancer (MIBC) Therapeutics under Development by
Companies 9
Muscle Invasive Bladder Cancer (MIBC) Therapeutics under Investigation by
Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Muscle Invasive Bladder Cancer (MIBC) Therapeutics – Products under
Development by Companies 15
Muscle Invasive Bladder Cancer (MIBC) Therapeutics – Products under
Investigation by Universities/Institutes 16
Companies Involved in Muscle Invasive Bladder Cancer (MIBC) Therapeutics
Development 17
Altor BioScience Corporation 17
Muscle Invasive Bladder Cancer (MIBC) – Therapeutics Assessment 18
3. Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
Gemcitabine + Cisplatin + Sunitinib - Drug Profile 24
Product Description 24
List of Figures
List of Tables are also include.
For more related Reports Plz follow The link:
Pipeline Review, H2 2012
http://www.aarkstore.com/search/viewresults.asp?search=Pipeline Review, H2
2012&PubId=&pagenum=1
Cholangiocellular Hepatoma – Pipeline Review, H2 2012
Hormone Refractory Breast Cancer – Pipeline Review, H2 2012
Muscle Invasive Bladder Cancer (MIBC) – Pipeline Review, H2 2012
Refractory Multiple Myeloma – Pipeline Review, H2 2012
Epithelial Ovarian Cancer – Pipeline Review, H2 2012
Neuro Endocrine (Carcinoid) Carcinoma – Pipeline Review, H2 2012
4. B-Cell Leukemia – Pipeline Review, H2 2012
Malignant Neoplasms – Pipeline Review, H2 2012
Recurrent Malignant Glioma – Pipeline Review, H2 2012
Endobronchial Cancer – Pipeline Review, H2 2012
Leiomyosarcoma – Pipeline Review, H2 2012
Transitional Cell Cancer (Urothelial Cell Cancer) – Pipeline Review, H2 2012
Esophageal Tumor – Pipeline Review, H2 2012
Malignant Pleural Mesothelioma – Pipeline Review, H2 2012
Search More Reports Related to This Category :
Pharmaceuticals and Healthcare
http://www.aarkstore.com/search/viewresults.asp?search=Pharmaceuticals and
Healthcare&PubId=&pagenum=1
You can also request for sample page of above mention reports on
sample@aarkstore.com
For More details Plz do contact :
Aarkstore Enterprise
Lavanya